This study investigates liver metastases in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
The focus is on evaluating innovative immune, gene, and cell therapy approaches to understand their effects on the liver's microenvironment and their potential as therapeutic tools.
- Who can participate: Adults aged 18 and older with liver metastases from CRC or PDAC are eligible. Key factors include confirmed diagnosis and the ability to provide informed consent.
- Study details: Participants will undergo various assessments to characterize their tumors. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last 7 years.